Affiliation:
1. R. M. Alden Research Laboratory, Santa Monica, California 90404
2. David Geffen School of Medicine at UCLA, Los Angeles, California 90073
Abstract
ABSTRACT
Tests of dalbavancin's in vitro activity against 209 aerobic and 120 anaerobic isolates from pretreatment diabetic foot infections showed an MIC
90
of ≤0.125 μg/ml against methicillin-susceptible
Staphylococcus aureus
(MSSA), methicillin-resistant
S. aureus
(MRSA), and 120 anaerobes (
Clostridium perfringens
, other clostridia,
Peptoniphilus asaccharolyticus
,
Finegoldia magna
, and
Anaerococcus prevotii
), compared to respective MIC
90
s for MSSA and MRSA of 0.5 and 1 μg/ml for vancomycin, 4 and 4 μg/ml for linezolid, 0.5 and 0.5 μg/ml for daptomycin, and 0.25 and >8 μg/ml for clindamycin.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献